Kennedy Capital Management Inc. lifted its position in Heron Therapeutics Inc (NASDAQ:HRTX) by 14.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 199,873 shares of the biotechnology company’s stock after purchasing an additional 24,873 shares during the quarter. Kennedy Capital Management Inc.’s holdings in Heron Therapeutics were worth $4,885,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Advisor Group Inc. grew its holdings in shares of Heron Therapeutics by 96.4% in the first quarter. Advisor Group Inc. now owns 1,416 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 695 shares during the period. Parallel Advisors LLC grew its holdings in shares of Heron Therapeutics by 247.4% in the first quarter. Parallel Advisors LLC now owns 1,685 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 1,200 shares during the period. Pearl River Capital LLC grew its holdings in shares of Heron Therapeutics by 1,900.0% in the first quarter. Pearl River Capital LLC now owns 2,000 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 1,900 shares during the period. US Bancorp DE purchased a new stake in shares of Heron Therapeutics in the first quarter valued at about $57,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Heron Therapeutics by 24.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,747 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 929 shares during the period.

HRTX stock traded up $0.07 during mid-day trading on Wednesday, hitting $17.11. 20,717 shares of the company were exchanged, compared to its average volume of 1,057,223. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.40 and a quick ratio of 4.06. The firm has a market cap of $1.40 billion, a PE ratio of -7.02 and a beta of 1.61. Heron Therapeutics Inc has a 12-month low of $16.20 and a 12-month high of $42.90.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.30). The company had revenue of $31.60 million for the quarter, compared to analysts’ expectations of $28.04 million. Heron Therapeutics had a negative return on equity of 49.22% and a negative net margin of 194.43%. The company’s quarterly revenue was up 172.4% compared to the same quarter last year. During the same period last year, the business earned ($1.09) EPS. Sell-side analysts anticipate that Heron Therapeutics Inc will post -2.66 EPS for the current fiscal year.

In other Heron Therapeutics news, Director Waage Christian acquired 1,400 shares of the stock in a transaction dated Wednesday, May 15th. The stock was acquired at an average price of $18.04 per share, with a total value of $25,256.00. Following the completion of the purchase, the director now owns 1,400 shares in the company, valued at approximately $25,256. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director John Poyhonen acquired 3,000 shares of the stock in a transaction dated Wednesday, May 22nd. The stock was acquired at an average cost of $17.55 per share, with a total value of $52,650.00. Following the purchase, the director now owns 13,000 shares of the company’s stock, valued at approximately $228,150. The disclosure for this purchase can be found here. Company insiders own 12.56% of the company’s stock.

HRTX has been the subject of a number of analyst reports. Cantor Fitzgerald lowered shares of Heron Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, March 4th. BidaskClub raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 20th. ValuEngine raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 22nd. Northland Securities set a $55.00 target price on shares of Heron Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $38.00 target price on shares of Heron Therapeutics in a research note on Wednesday, May 1st. Two research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $51.20.

TRADEMARK VIOLATION WARNING: “Kennedy Capital Management Inc. Has $4.89 Million Position in Heron Therapeutics Inc (NASDAQ:HRTX)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/kennedy-capital-management-inc-has-4-89-million-position-in-heron-therapeutics-inc-nasdaqhrtx/3039391.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Article: Technical Analysis

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.